Tobacco Use Disorder

Pipeline Programs

Companies

Clinical Trials

1 recruiting

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

16 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

Cessation TherapeuticsCA - San Diego

1 program

Self-determination Intervention for Tobacco DependencePhase 41 trial

Active Trials

NCT00178685Completed837Est. Aug 2008

PfizerNEW YORK, NY

4 programs

VareniclinePhase 21 trial

Deep Repetitive Transcranial Magnetic StimulationN/A

Smoking-induced Dopamine Release: a [11C]-(+)-PHNO PET Study in HumansN/A1 trial

VareniclineN/A1 trial

Active Trials

NCT01302262Completed10Est. Mar 2013

NCT01308736Completed73Est. Feb 2014

NCT00595868Completed220Est. Jan 2010

Human BioSciencesWV - Martinsburg

2 programs

Pediatric residency training on tobaccoPhase 21 trial

Modified Project Toward No Tobacco UseN/A1 trial

Active Trials

NCT00059514Completed2,300Est. May 2006

NCT00098215Unknown4,000Est. Feb 2006

Oregon TherapeuticsFrance - Paris

2 programs

Active rTMSPhase 21 trial

Web + PhonePhase 21 trial

Active Trials

NCT03497299Withdrawn0Est. Aug 2022

NCT00820495Completed1,683Est. May 2012

ViiV HealthcareNC - Durham

3 programs

Nicotine Prototype Mini lozengePhase 1

Treatment A: Nicorette 2 mg coated mint gumPhase 1

GeneSysIndia - Hyderabad

1 program

CHERLPhase 11 trial

Active Trials

NCT00269009UnknownEst. Feb 2007

Grand MedicalIsrael - Ramat Gan

1 program

CHERLPhase 1

Martin PharmaceuticalsNY - New York

1 program

ModafinilNicotine Replacement TherapyPhase 11 trial

Active Trials

NCT00258479Completed24Est. Dec 2011

GSKLONDON, United Kingdom

3 programs

Nicotine Prototype Mini lozengePHASE_11 trial

Treatment A: Nicorette 2 mg coated mint gumPHASE_11 trial

Active Trials

NCT03541044Completed46Est. Mar 2019

NCT03543137Completed37Est. Nov 2018

NCT02688374Completed45Est. Jun 2016

Johnson & JohnsonNEW BRUNSWICK, NJ

2 programs

CHERLPHASE_1

Bupropion SRPHASE_41 trial

Active Trials

NCT00119210Terminated40Est. Mar 2006

Innovation PharmaceuticalsMA - Wakefield

1 program

Control groupN/A1 trial

Active Trials

NCT05885659Recruiting90Est. Dec 2025

BrainsWayJerusalem, Israel

1 program

Deep Repetitive Transcranial Magnetic StimulationN/A1 trial

Active Trials

NCT04083144Completed50Est. Dec 2022

Alliance PharmaceuticalsUK - Wiltshire

1 program

Fresh limeN/A1 trial

Active Trials

NCT01333202Completed100Est. Sep 2009

Bryan CorporationOH - Cincinnati

1 program

QuitbuddyN/A1 trial

Active Trials

NCT05625685Withdrawn0Est. Nov 2023

Hope MedicineChina - Pudong

1 program

QuitbuddyN/A

Angeles TherapeuticsCA - Los Angeles

1 program

repetitive transcranial magnetic stimulationN/A1 trial

Active Trials

NCT03827265Completed60Est. Aug 2024

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

Johnson & JohnsonBupropion SR

Cessation TherapeuticsSelf-determination Intervention for Tobacco Dependence

Oregon TherapeuticsActive rTMS

Oregon TherapeuticsWeb + Phone

PfizerVarenicline

Human BioSciencesPediatric residency training on tobacco

GSKNicotine Prototype Mini lozenge

GSKTreatment A: Nicorette 2 mg coated mint gum

GeneSysCHERL

Martin PharmaceuticalsModafinilNicotine Replacement Therapy

Bryan CorporationQuitbuddy

Innovation PharmaceuticalsControl group

BrainsWayDeep Repetitive Transcranial Magnetic Stimulation

Angeles Therapeuticsrepetitive transcranial magnetic stimulation

Showing 15 of 19 trials with date data

Clinical Trials (19)

Total enrollment: 9,615 patients across 19 trials

NCT00119210 Johnson & JohnsonBupropion SR

Pilot Study of Bupropion for Smoking Cessation in Postpartum Non-breastfeeding Women

Start: Mar 2005Est. completion: Mar 200640 patients

Phase 4Terminated

NCT00178685 Cessation TherapeuticsSelf-determination Intervention for Tobacco Dependence

Smokers' Health Project: Self-Determination and Maintaining Tobacco Abstinence

Start: Aug 2004Est. completion: Aug 2008837 patients

Phase 4Completed

NCT03497299 Oregon TherapeuticsActive rTMS

Combining rTMS With Varenicline to Prevent Smoking Lapse in Schizophrenia

Start: Jul 2018Est. completion: Aug 20220

Phase 2Withdrawn

NCT00820495 Oregon TherapeuticsWeb + Phone

Effectiveness of a Web-Assisted Quitline for Smokeless Tobacco Users

Start: May 2009Est. completion: May 20121,683 patients

Phase 2Completed

NCT00595868 PfizerVarenicline

Efficacy of Varenicline in Ambivalent Smokers

Start: Mar 2008Est. completion: Jan 2010220 patients

Phase 2Completed

NCT00098215 Human BioSciencesPediatric residency training on tobacco

Pediatric Residency Training On Tobacco

Start: Mar 2001Est. completion: Feb 20064,000 patients

Phase 2Unknown

NCT03541044 GSKNicotine Prototype Mini lozenge

A Bioequivalence Study of Two Nicotine Lozenges in Fasting Conditions in Healthy Smokers

Start: Jun 2018Est. completion: Mar 201946 patients

Phase 1Completed

NCT03543137 GSKNicotine Prototype Mini lozenge

To Assess the Bioequivalence of the 4mg Prototype Mini Nicotine Lozenge to the Reference Product (Nicorette) in Healthy Smokers

Start: Jun 2018Est. completion: Nov 201837 patients

Phase 1Completed

NCT02688374 GSKTreatment A: Nicorette 2 mg coated mint gum

A Bioequivalence Study of Three, 2 mg Nicotine Chewing Gums (Two Tests and One Reference) in Healthy Adult Smokers

Start: Mar 2016Est. completion: Jun 201645 patients

Phase 1Completed

NCT00269009 GeneSysCHERL

CHERL, Connecting Primary Care Patients With Community Resources to Facilitate Behavior Change

Start: Jan 2006Est. completion: Feb 2007

Phase 1Unknown

NCT00258479 Martin PharmaceuticalsModafinilNicotine Replacement Therapy

Safety of Combining Modafinil and Nicotine Replacement Therapy in Treating Nicotine Dependent Adolescents

Start: Jun 2003Est. completion: Dec 201124 patients

Phase 1Completed

NCT05625685 Bryan CorporationQuitbuddy

Equitable Smoking Relapse Prevention

Start: Oct 2023Est. completion: Nov 20230

N/AWithdrawn

NCT05885659 Innovation PharmaceuticalsControl group

Smoking Cessation Program for Adults With Type 2 Diabetes Mellitus (DiMe-SALUD2 Project)

Start: Sep 2023Est. completion: Dec 202590 patients

N/ARecruiting

NCT04083144 BrainsWayDeep Repetitive Transcranial Magnetic Stimulation

Deep rTMS and Varenicline for Smoking Cessation

Start: Aug 2019Est. completion: Dec 202250 patients

N/ACompleted

NCT03827265 Angeles Therapeuticsrepetitive transcranial magnetic stimulation

Transcranial Magnetic Stimulation and Tobacco Use Disorder

Start: Feb 2019Est. completion: Aug 202460 patients

N/ACompleted

NCT01302262 PfizerSmoking-induced Dopamine Release: a [11C]-(+)-PHNO PET Study in Humans

Smoking-induced Dopamine Release: a [11C]-(+)-PHNO PET Study in Humans

Start: Feb 2011Est. completion: Mar 201310 patients

N/ACompleted

NCT01308736 PfizerVarenicline

Varenicline-Aided Cigarette Reduction in Smokers Not Ready to Quit

Start: Jan 2011Est. completion: Feb 201473 patients

N/ACompleted

NCT01333202 Alliance PharmaceuticalsFresh lime

Fresh Lime Alone for Smoking Cessation

Start: Mar 2009Est. completion: Sep 2009100 patients

N/ACompleted

NCT00059514 Human BioSciencesModified Project Toward No Tobacco Use

Tobacco Use Among Arab American Youth

Start: May 2000Est. completion: May 20062,300 patients

N/ACompleted

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 9,615 patients

16 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.